In this episode, we visit with Christopher Furmon who leads Vitro based in Colorado. Christopher doesn't come from a traditional biopharma track. Instead, he spent decades helping build the financial juggernaut Janus.
Vitro Biopharma has a goal to become a leader in developing differentiated product candidates in a rapid and efficient manner for the immunology and inflammatory market; and ultimately, to address well-established multi-billion-dollar commercial markets.
The team has over 30 years of drug discovery and development experience that has enabled them to identify and advance multiple product candidates from preclinical studies into clinical trials. Specifically, their extensive knowledge of immunology and inflammatory conditions informs their decision making to advance the scientific and clinical path to demonstrate proof-of-concept, with the goal of achieving an efficient timeframe and cost-effective budget. Visit them at www.vitrobiopharma.com
Torque3 is developing a neurorehabilitation solution that has shown in early testing to result in significantly better recovery outcomes. A wealth of research over...
John P. Pigott, MD, FACS, currently serves as Chief Innovations Officer/Strategic Business Development for ProMedica and ProMedica Innovations, where he works with thought leaders...
TMI is developing the POINT-GUARD, the first and only cerebral embolic protection device with dynamic Double-Edge Sealing. The seal adapts and conforms to complex...
